[Correspondence] CALLA trial: immunotherapy in locally advanced cervical cancer – Authors’ reply

The CALLA trial was designed to determine the efficacy and safety of the anti-PD-L1 antibody, durvalumab, with and after standard-of-care concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in women with locally advanced cervical cancer.1 Progression-free survival was not substantially improved in a biomarker unselected, all-comers population (hazard ratio [HR] 0·84; 95% CI 0·65–1·08; p=0·17), with no new safety signals identified.